Ultimovacs ASA: Notification of major holdings

Oslo, 9 January 2025:Reference is made to the stock exchange notices published by Ultimovacs ASA (the " Company ") on (i) 17 December 2024 regarding the contemplated business combination between the Company and Zelluna Immunotherapy AS (the " Business Combination ") and the fully committed private placement with gross proceeds of approx. NOK 51.7 million (the " Private Placement ") and (ii) today on 9 January 2025 regarding the approval by an extraordinary general meeting of the Company...

Oslo, 09/01/2025 (informazione.news - comunicati stampa - salute e benessere)

Oslo, 9 January 2025: Reference is made to the stock exchange notices published by Ultimovacs ASA (the " Company ") on (i) 17 December 2024 regarding the contemplated business combination between the Company and Zelluna Immunotherapy AS (the " Business Combination ") and the fully committed private placement with gross proceeds of approx. NOK 51.7 million (the " Private Placement ") and (ii) today on 9 January 2025 regarding the approval by an extraordinary general meeting of the Company (the " EGM ") of relevant resolutions related to the Business Combination and the Private Placement. The Business Combination and the Private Placement are hereinafter referred to as the " Transactions ".

Following the EGM's resolutions to approve the issuance of 167,864,598 shares in aggregate through the Transactions, and subject to completion of the Transactions, certain of the Company's and Zelluna Immunotherapy AS' major shareholders will cross threshold for disclosure of shareholdings pursuant to Chapter 4 of the Norwegian Securities Trading Act as follows:

This information is subject to the disclosure requirements pursuant to Section 4-2 the Norwegian Securities Trading Act.